How to Reconstitute MK-677 (Ibutamoren): Step-by-Step Reconstitution

What Is MK-677 and Why Does Reconstitution Matter?

MK-677 (Ibutamoren) is a non-peptide ghrelin receptor agonist and growth hormone secretagogue. It is orally bioavailable in its capsule form, but research-grade suppliers often ship it as lyophilized (freeze-dried) powder because powder is more stable during long-distance shipping at ambient temperature. Reconstituting that powder incorrectly, using the wrong diluent, wrong volume, or non-sterile technique, risks microbial contamination, incorrect dosing, or chemical degradation that negates any intended effect.

A 2008 Phase II trial published in the Journal of Clinical Endocrinology and Metabolism confirmed that oral MK-677 at 25 mg/day for 24 weeks significantly increased serum IGF-1 and 24-hour mean GH concentration in 65 healthy older adults (P<0.001) [1]. That same trial found that the compound's pharmacokinetic consistency depended on stable formulation and controlled storage, which underscores why reconstitution technique matters in a research setting.

Why Powder Instead of Oral Capsule?

Research-grade suppliers ship lyophilized powder because:

• Powder form is chemically stable at room temperature for up to 24 months before reconstitution.
• A liquid solution allows dose titration that a fixed-dose capsule does not.
• Some investigational protocols use subcutaneous injection to bypass first-pass metabolism, although oral bioavailability of MK-677 is already approximately 60 to 70% [2].

Regulatory Context

The FDA has not approved MK-677 for any clinical indication. It appeared briefly in clinical development (Merck's MK-0677 program) but was never brought to market. Any use outside an approved Investigational New Drug (IND) application is for research purposes only. USP Chapter <797> governs sterile compounding standards that apply whenever you prepare an injectable solution [3].

Supplies You Need Before You Start

Gathering every item before opening a vial prevents mid-procedure contamination. Missing one item and leaving the vial unsealed increases microbial risk substantially.

Complete Supply List

| Item | Specification | Why It Matters | |---|---|---| | MK-677 lyophilized powder vial | 25 mg (typical) | Verify mg on label before calculating volume | | Bacteriostatic water for injection | USP grade, 0.9% benzyl alcohol | Benzyl alcohol inhibits microbial growth for up to 28 days [4] | | Insulin syringe | 1 mL, 28 to 31 gauge, 0.5-inch needle | Fine gauge reduces vial stopper coring | | Alcohol swabs | 70% isopropyl alcohol | Stopper and skin disinfection | | Sterile gloves | Nitrile, powder-free | Reduces particulate contamination | | Permanent marker | Any | Label vial with date and concentration | | Refrigerator | 2 to 8 °C, away from door | Stable temperature prolongs shelf life |

Never substitute sterile water for injection (SWFI) for bacteriostatic water if you plan to store the solution longer than 24 hours. SWFI contains no preservative and becomes a contamination risk within hours of reconstitution [4].

Step-by-Step Reconstitution Protocol

This protocol follows USP <797> low-risk compounding principles for sterile preparations [3]. Work on a clean, hard surface. Ideally use a laminar flow hood; if one is unavailable, close windows, turn off fans, and work away from air vents.

Step 1: Hand Hygiene and Surface Preparation

Wash hands with soap and water for at least 20 seconds. Dry with a lint-free towel. Put on sterile nitrile gloves. Wipe the work surface with a 70% isopropyl alcohol swab and allow it to dry for 30 seconds. Do not blow on the surface or wave hands over it after cleaning.

Step 2: Inspect the Vial

Hold the MK-677 vial up to light. The powder should be white to off-white and uniformly distributed. Discard any vial showing:

• Visible clumping or discoloration (yellow or brown)
• Broken seal or compromised stopper
• No lot number or expiration date on the label

Confirm the labeled quantity (commonly 25 mg) before calculating your reconstitution volume.

Step 3: Swab Stoppers

Swab the rubber stopper of the MK-677 vial and the bacteriostatic water vial with separate 70% isopropyl alcohol swabs. Allow each stopper to air-dry for at least 15 seconds. Do not touch the stopper after swabbing.

Step 4: Draw Bacteriostatic Water

Pick up the insulin syringe. Insert the needle through the center of the bacteriostatic water vial stopper at a 45-degree angle to reduce coring. Draw back the plunger slowly to the volume you calculated (see the dosing calculator section below). Withdraw the needle smoothly.

For a standard 25 mg vial targeted at a 12.5 mg/mL concentration, draw 2.0 mL total. Because a 1 mL insulin syringe holds only 1 mL, you will inject in two 1 mL aliquots.

Step 5: Inject Diluent Into the Powder Vial

Insert the needle into the MK-677 vial stopper. Angle the needle so the stream of bacteriostatic water runs down the inner glass wall of the vial rather than directly onto the powder cake. Direct impingement can shear the molecule and reduce potency [5].

Inject slowly. Do not force the plunger. If resistance appears, check that the vial has a vent needle or reposition the syringe angle slightly.

Repeat with the second 1 mL aliquot if using a 1 mL syringe.

Step 6: Mix Gently

Remove the needle. Hold the vial between your palms and roll it gently for 20 to 30 seconds. Do not shake. Shaking creates foam, which introduces air bubbles that make accurate dosing harder and may degrade some peptides through mechanical agitation [5].

The solution should be clear and colorless within 60 seconds. Persistent cloudiness after 2 minutes of gentle rolling indicates incomplete dissolution or possible degradation. Discard a cloudy vial.

Step 7: Label the Vial

Write on the vial immediately with a permanent marker:

• Compound name: MK-677
• Concentration: 12.5 mg/mL (or your calculated concentration)
• Preparation date
• Expiration date: 28 days from today
• Your initials

USP <797> requires complete labeling of all compounded sterile preparations [3].

Step 8: Store Correctly

Place the vial upright in a refrigerator set to 2 to 8 °C. Keep it away from the door (temperature fluctuates there). Do not freeze a reconstituted solution; freeze-thaw cycles degrade the compound and may cause precipitation [5].

MK-677 Concentration and Dosing Calculator

The table below covers the three most common vial sizes and four target concentrations. Find your vial size in the left column, select your target concentration, and the table shows how much bacteriostatic water to add and how many microliters to draw per dose on a standard 100-unit (1 mL) insulin syringe.

Reconstitution Volume Table

| Vial Size | Target Concentration | Bacteriostatic Water to Add | Volume per 10 mg Dose | Volume per 25 mg Dose | |---|---|---|---|---| | 10 mg | 5 mg/mL | 2.0 mL | 0.20 mL (20 units) | N/A | | 10 mg | 10 mg/mL | 1.0 mL | 0.10 mL (10 units) | N/A | | 25 mg | 12.5 mg/mL | 2.0 mL | 0.80 mL (80 units) | 2.0 mL (200 units*) | | 25 mg | 25 mg/mL | 1.0 mL | 0.40 mL (40 units) | 1.0 mL (100 units) | | 50 mg | 10 mg/mL | 5.0 mL | 1.0 mL (100 units) | 2.5 mL† | | 50 mg | 25 mg/mL | 2.0 mL | 0.40 mL (40 units) | 1.0 mL (100 units) |

*Exceeds 1 mL syringe; use a 3 mL syringe for this draw. †Use a 3 mL syringe or split across two draws.

How to Read Your Insulin Syringe

A 100-unit insulin syringe holds 1 mL. Each unit mark equals 0.01 mL. So:

• 10 units = 0.10 mL
• 20 units = 0.20 mL
• 40 units = 0.40 mL
• 80 units = 0.80 mL

The standard investigational dose of MK-677 used in the Nass et al. 2008 trial was 25 mg/day [1]. A 25 mg/mL solution makes that dose a clean 1.0 mL (100 units) pull, which minimizes mental math errors.

Choosing the Right Concentration

Higher concentrations mean smaller injection volumes, which is generally more comfortable for subcutaneous administration. A 25 mg/mL solution gives a 1 mL pull for the 25 mg dose. A 12.5 mg/mL solution doubles that to 2 mL, which is workable orally (drop under tongue) but uncomfortable as a subcutaneous injection.

Syringe Selection and Injection Technique

Which Syringe to Use

For volumes up to 1 mL, a 28 to 31 gauge, 0.5-inch (12.7 mm) insulin syringe is standard. For volumes between 1 mL and 3 mL, use a 3 mL Luer-lock syringe with a 25 to 27 gauge, 0.5-inch needle.

Finer gauge needles (30 to 31 G) cause less discomfort but are slightly more prone to bending if technique is not smooth. A 28 G needle is a good middle ground for most users.

Subcutaneous Injection Sites

If the protocol calls for subcutaneous delivery, common sites are:

• Abdomen: 2 inches from the navel, alternating sides
• Upper thigh: lateral aspect, mid-thigh
• Upper arm: posterior lateral surface

Pinch a fold of skin. Insert the needle at a 45-degree angle for thin individuals or 90 degrees if there is substantial subcutaneous tissue. Inject slowly over 5 to 10 seconds. Release the skin fold before withdrawing the needle [6].

Oral or Sublingual Administration of Reconstituted Solution

Because MK-677 has oral bioavailability of approximately 60 to 70% [2], some research protocols administer the reconstituted solution orally by drawing the calculated volume into an insulin syringe (no needle attached) and releasing it under the tongue. Hold for 30 seconds, then swallow. This route avoids injection entirely and is the simpler option for non-clinical researchers.

Stability, Storage, and Shelf Life

Unreconstituted Powder

Lyophilized MK-677 powder stored at -20 °C in a sealed vial is stable for 24 to 36 months according to standard peptide stability data compiled by USP compounding references [3]. At room temperature (15 to 25 °C), expect 12 to 18 months of stability in a sealed, dry environment away from UV light.

Reconstituted Solution

After mixing with bacteriostatic water, the solution should be:

• Stored at 2 to 8 °C (refrigerator, not freezer)
• Used within 28 days
• Discarded if any cloudiness, color change, or visible particulate appears

The 28-day window comes from the antimicrobial efficacy limit of 0.9% benzyl alcohol as a preservative in multi-dose vials, consistent with USP <797> guidelines [3] [4].

Signs a Vial Should Be Discarded

Discard immediately if you observe:

• Cloudiness that does not clear after 2 minutes of rolling
• Yellow or amber discoloration
• Visible particles or flakes
• Any odor from the opened vial
• Stopper that appears punched through or damaged

Safety Profile and Monitoring

MK-677 is not a benign supplement. Recruiting IGF-1 and GH has measurable metabolic consequences that warrant monitoring in any research application.

Known Adverse Effects

The 24-week JCEM trial by Nass et al. Reported these adverse events at 25 mg/day [1]:

• Increased fasting glucose (mean +3.6 mg/dL, P<0.05)
• Increased fasting insulin
• Mild peripheral edema in approximately 20% of participants
• Transient increase in appetite (expected ghrelin-agonist effect)

A separate 2-year MK-677 study in 292 hip-fracture patients published in the Journal of the American Geriatrics Society (2008) found no increase in cancer incidence but did confirm glucose intolerance as a recurring concern [7].

Recommended Monitoring Parameters

| Parameter | Baseline | Every 3 Months | |---|---|---| | Fasting glucose | Yes | Yes | | HbA1c | Yes | Yes | | IGF-1 | Yes | Yes | | GH (random or stimulated) | Optional | Optional | | Blood pressure | Yes | Yes | | Serum electrolytes | Yes | At 3 months |

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states that IGF-1 should be maintained within age-adjusted normal ranges during any GH-axis therapy to avoid adverse outcomes [8]. That principle applies to secretagogue use as well.

Drug Interactions

MK-677 may amplify insulin resistance when combined with corticosteroids or other agents that raise blood glucose. Co-administration with insulin or oral hypoglycemics may require dose adjustment. Consult a prescribing clinician before combining MK-677 with any glucose-regulating medication.

Common Reconstitution Mistakes and How to Avoid Them

Mistake 1: Using Sterile Water Instead of Bacteriostatic Water

Sterile water for injection contains no preservative. A reconstituted vial must be used within 24 hours or discarded. Bacteriostatic water with 0.9% benzyl alcohol extends safe multi-dose use to 28 days [4]. Using the wrong diluent is the single most common error in research peptide preparation.

Mistake 2: Shaking the Vial

Mechanical agitation through shaking can introduce foam and potentially disrupt disulfide bonds or other structural features in the compound [5]. Roll, do not shake.

Mistake 3: Injecting Water Directly Onto the Powder

Direct stream impingement onto the lyophilized cake accelerates local degradation. Always aim the diluent stream at the vial wall and let it run down gently.

Mistake 4: Skipping the Label

An unlabeled vial left in a shared refrigerator is a contamination and dosing error waiting to happen. Label immediately, every time.

Mistake 5: Miscalculating the Concentration

The formula is simple:

Concentration (mg/mL) = Vial amount (mg) / Volume of diluent added (mL)

A 25 mg vial plus 2 mL bacteriostatic water = 25/2 = 12.5 mg/mL. Double-check arithmetic before the first draw.

USP <797> and Compounding Standards Applicable to MK-677 Preparation

USP Chapter <797> sets the minimum quality standards for compounded sterile preparations in the United States [3]. While <797> formally applies to licensed compounding pharmacies, its principles represent the scientific baseline for anyone preparing a sterile injectable solution:

• Immediate-use preparations (single dose, administered within 1 hour): can be prepared without a controlled environment.
• Low-risk preparations (multi-dose, stored up to 28 days): require a clean room or ISO Class 5 environment (laminar flow hood).
• Beyond-use dating (BUD): 28 days at controlled refrigerator temperature for low-risk preparations with a bacteriostatic preservative.

For non-pharmacy researchers, the practical minimum is clean gloves, a freshly disinfected surface, and alcohol-swabbed stoppers. A laminar flow hood, though not always accessible, reduces airborne particulate contamination by several orders of magnitude.

The FDA's 503B outsourcing facility framework offers an alternative: purchasing MK-677 from a registered 503B compounder provides a preparation already made under USP <797> conditions, removing the reconstitution burden from the end user [9].

Frequently Asked Questions